Zeke Capital Advisors’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
$420K Sell
9,073
-1
-0% -$43 0.03% 270
2022
Q3
$351K Sell
9,074
-123
-1% -$4.93K 0.03% 279
2022
Q2
$343K Sell
9,197
-84
-0.9% -$3.42K 0.02% 290
2022
Q1
$411K Buy
+9,281
New +$402K 0.02% 272
2020
Q1
Sell
-19,385
Closed -$877K 275
2019
Q4
$877K Sell
19,385
-395
-2% -$16.5K 0.07% 233
2019
Q3
$805K Buy
19,780
+1,200
+6% +$50.8K 0.07% 246
2019
Q2
$799K Sell
18,580
-2,231
-11% -$85.8K 0.08% 235
2019
Q1
$799K Sell
20,811
-1,160
-5% -$44.3K 0.07% 234
2018
Q4
$776K Sell
21,971
-4,670
-18% -$169K 0.07% 248
2018
Q3
$1.03M Hold
26,641
0.08% 243
2018
Q2
$871K Buy
26,641
+599
+2% +$18.1K 0.08% 209
2018
Q1
$711K Buy
26,042
+15,754
+153% +$428K 0.07% 267
2017
Q4
$255K Sell
10,288
-18,634
-64% -$514K 0.03% 429
2017
Q3
$844K Buy
28,922
+19,895
+220% +$549K 0.12% 138
2017
Q2
$250K Hold
9,027
0.05% 231
2017
Q1
$225K Buy
+9,027
New +$220K 0.05% 232

Other funds holding BSX

Zeke Capital Advisors's BSX Position: Q4 2022 in Review

Zeke Capital Advisors reduced its Boston Scientific (BSX) stake by 0.01% in Q4 2022, selling an estimated $43 and leaving 9,073 shares worth $420K. The position accounts for 0.03% of the portfolio, ranked #270.

Zeke Capital Advisors first reported a position in BSX in Q1 2017 and has held it in 16 quarters since. The position peaked at $1.03M in Q3 2018. 928 funds tracked by Wall St. Rank hold BSX as of Q4 2022.

  • Zeke Capital Advisors held 9,073 shares of Boston Scientific worth $420K as of Q4 2022.
  • Zeke Capital Advisors sold 1 Boston Scientific share in Q4 2022, an estimated $43.
  • Boston Scientific made up 0.03% of Zeke Capital Advisors's portfolio in Q4 2022, its #270 holding.
  • Zeke Capital Advisors first reported a position in Boston Scientific in Q1 2017 and has held it in 16 quarters since.
  • Zeke Capital Advisors's Boston Scientific position peaked at $1.03M in Q3 2018.
  • 928 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.